Metabolic Research
RETATRUTIDE PEN
Pen · 6 strengths available
Register Interest
Currently “Available for Purchase — out of stock”. Leave your email and we will notify you when availability changes.
For in-vitro laboratory research only. Not for human or veterinary use. VQ Health does not provide dosing, administration or protocol guidance.
Research reference material in pen format, supplied in 6 strengths.
Compound Dossier
Research Overview
Educational research content. Established, peer-reviewed findings are clearly distinguished from investigational research.
Overview+
Retatrutide — Compound Overview
Retatrutide (LY3437943) is an investigational single-molecule triple agonist of the GIP, GLP-1 and glucagon receptors. It is among the most closely watched compounds in contemporary metabolic research because it engages three complementary signalling pathways at once.
Investigational status
Retatrutide is not an authorised medicine anywhere in the world. It remains in clinical development. VQ Health supplies it strictly as an in-vitro research reference compound. No dosing, administration or protocol information is provided.
Research Context+
Research Context
Why triple agonism attracted scientific interest
Single-pathway incretin agonists (GLP-1) established the field. Dual agonism (GIP + GLP-1, e.g. tirzepatide) showed that combining pathways can alter outcomes in clinical research. Adding glucagon receptor agonism is scientifically distinctive because glucagon is studied for its roles in hepatic glucose production, energy expenditure and lipid metabolism — pathways that GLP-1/GIP do not directly engage. Triple-agonist research asks whether three-way signalling can be balanced safely and what each receptor contributes.
Preclinical vs clinical research
- Established (peer-reviewed): phase 1 and phase 2 clinical data on safety signals, glucose and body-weight endpoints in studied populations; receptor pharmacology from preclinical characterisation.
- Investigational: phase 3 programme outcomes, long-term safety, the relative contribution of glucagon-receptor engagement to observed effects, and most mechanistic hypotheses from animal and in-vitro models. These are open research questions, not conclusions.
Mechanism / Area of Study+
Mechanisms Being Studied
GLP-1 receptor pathway
Glucose-dependent insulin secretion, glucagon suppression and central satiety signalling in experimental models.
GIP receptor pathway
Insulinotropic effects and adipose-tissue lipid handling in preclinical systems.
Glucagon receptor pathway
Hepatic glucose output, amino-acid metabolism and energy expenditure in experimental models — the differentiating arm of triple-agonist research.
Key terminology
- Agonist — a molecule that activates a receptor. Triple agonist — one molecule activating three receptor types.
- Incretin — gut-derived hormone that amplifies glucose-dependent insulin secretion (GLP-1, GIP).
- Phase 1/2/3 — successive stages of clinical research: safety, dose-ranging/signals, confirmatory trials.
- Investigational — not approved for any medical use; studied only within research settings.
Published Research+
Published Research (selection)
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389:514-526.
- Rosenstock J et al. Retatrutide for type 2 diabetes — a phase 2 trial. Lancet 2023;402:529-544.
- Coskun T et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Cell Metab 2022;34:1234-1247.
These references describe research findings in studied settings. They are provided for scientific context only and imply nothing about any non-research use.
Documentation+
Documentation
Where a batch-specific Certificate of Analysis exists, it is linked on this page and searchable by batch number in the VQ COA library. Certificates document analytical testing (identity/purity) of the supplied batch only.
Important Information+
Important Information
For in-vitro laboratory research only. Not for human or veterinary use. Retatrutide is an investigational compound. VQ Health provides no dosing, administration, protocol or treatment information, and nothing on this page is medical advice.
This material is supplied strictly for in-vitro laboratory research. It is a reference compound intended for analytical, assay-development and in-vitro experimental work only. It is not a medicine, food supplement or cosmetic product, and it is not intended for human or veterinary use under any circumstances. VQ Health does not provide dosing, administration or protocol guidance of any kind.
Related Research
